Applied intelligence in clinical drug development: Potential benefits and emerging concerns
Author:
Open Access
- 27 May 2025
- journal article
- review article
- Published by Wolters Kluwer Health in Perspectives in Clinical Research
- Vol. 16 (3) , 127-131
Abstract
The use of artificial intelligence (AI) technology and machine learning (ML) is growing exponentially and is moving from AI to applied intelligence. Pharma industry is actively exploring the potential use of AI tools in new product discovery and clinical development. Some of the practical applications of AI in clinical development are for improving the efficiency of enrollment, selection and stratification of participants, optimizing study treatment, enhancing compliance, data analysis, and pharmacovigilance. AI applications have been used for outcome prediction; covariate selection/confounding adjustment; anomaly detection; real-world data phenotyping; imaging, video, and voice analysis; endpoint assessment; and pharmacometric modeling in regulatory submissions. However, widespread applications of novel yet difficult-to-understand AI technology in clinical development would need balancing the benefits and risks and resolving issues of scientific validity, technical quality, and ethics. The article discusses the potential benefits and emerging concerns of applying AI in clinical drug development.Keywords
This publication has 14 references indexed in Scilit:
- Deep Learning Model for Predicting Immunotherapy Response in Advanced Non−Small Cell Lung CancerJAMA Oncology, 2025
- Matching patients to clinical trials with large language modelsNature Communications, 2024
- Randomised controlled trials evaluating artificial intelligence in clinical practice: a scoping reviewThe Lancet Digital Health, 2024
- The Future of Clinical TrialsJAMA, 2023
- Artificial intelligence and pharmacovigilance: What is happening, what could happen and what should happen?Health Policy and Technology, 2023
- Artificial Intelligence and Machine Learning in Clinical Medicine, 2023New England Journal of Medicine, 2023
- Landscape Analysis of the Application of Artificial Intelligence and Machine Learning in Regulatory Submissions for Drug Development From 2016 to 2021Clinical Pharmacology & Therapeutics, 2022
- Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI ExtensionBMJ, 2020
- Application of Augmented Intelligence for Pharmacovigilance Case Seriousness DeterminationDrug Safety, 2019
- Artificial Intelligence for Clinical Trial DesignTrends in Pharmacological Sciences, 2019